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Background: Fatty liver is associated with insulin resistance, dyslipidemia, and obesity and is therefore considered a
phenotype of metabolic syndrome. However, less is known regarding the metabolic abnormalities associated with
non-alcoholic fatty pancreatic disease (NAFPD; fatty pancreas). The present study was performed to ascertain
whether fatty pancreas is associated with specific metabolic risk factors and with metabolic syndrome as defined by
the Adult Treatment Panel III.
Methods: Five-hundred-fifty-seven healthy and consecutive subjects without known hypertension or diabetes and
who received a health investigation at the National Taiwan University Hospital Health Management Center were
enrolled in this retrospective study. Fatty pancreas was diagnosed via trans-abdominal ultrasonographic findings.
Results: Seventy-two (12.9%) subjects diagnosed with fatty pancreas comprised the fatty pancreas group, and
remaining subjects comprised the normal pancreas group. The presence of various demographic and metabolic risk
factors was recorded for all subjects, and the two groups were examined for statistically significant differences in
these factors. As compared to the absence of fatty pancreas, the presence of the disease was associated with older
age and with higher values for each of the following: BMI, abdominal girth/height, abdominal girth (both genders),
fasting and postprandial blood glucose, HbA1c, total cholesterol, triglycerides, LDL-cholesterol, systolic blood
pressure, and platelet count. In contrast to previously reported findings, serum amylase values were lower in the
fatty pancreas as compared to the control group.
Conclusion: The presence of fatty pancreas represents a meaningful manifestation of metabolic syndrome together
with obesity.
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Diabetes mellitusIntroduction
Unlike fat stored in subcutaneous adipocytes, visceral fat
and ectopic fat stored in tissues such as liver, heart,
muscle, and pancreas are both associated with obesity
and/or insulin resistance [1,2]. Fatty liver is reported to
be associated with insulins resistance, dyslipidemia, and
obesity and is therefore considered a phenotype of meta-
bolic syndrome [3-5]. However, only a few studies of the* Correspondence: cyw1965@gmail.com
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reproduction in any medium, provided the ormetabolic abnormalities associated with non-alcoholic
fatty pancreatic disease, termed NAFPD or fatty pancreas,
have been performed, and the clinical consequences of
fatty pancreas remain unclear (Figure 1).
Ogilvie, who first described fatty infiltration of the
pancreas in 1993, reported 17% pancreatic fat storage
for obese cadavers as compared with 9% for lean ones
[6]. Findings from studies with animals reveal that
pancreatic steatosis promotes islet cell abnormalities
resulting in hyperglycemia [7-9]. Additionally, findings
from older autopsy and transabdominal ultrasonography
studies reveal an association of fatty pancreas with
advanced age, obesity, and increased body fat [10].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The association between ectopic fat deposition and metabolic syndrome.
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associations for fatty pancreas including male gender,
age older than 60 years, hypertension, hepatic steatosis,
alcohol use, increased body mass index (BMI), impaired
insulin secretion, insulin resistance, visceral fat deposition,
elevated triglycerides (TG), increased alanine aminotrans-
ferase (ALT) values, β-cell dysfunction, and diabetes
[11-17]. Lee et al. [10,13] and Sepe et al. [10,13] suggested
that fatty pancreas is associated with an increased
frequency of metabolic syndrome and correlates with
the number of parameters of metabolic syndrome. The
present study was undertaken to ascertain whether
NAFPD is associated with specific demographic and
metabolic risk factors and with metabolic syndrome as
defined by the National Cholesterol Education Program
Adult Treatment Panel III (ATP III).
Materials and methods
Patients
Five-hundred-fifty-seven healthy and consecutive subjects
not known to have hypertension or diabetes and who had
a health investigation at the National Taiwan University
Hospital Health Management Center were analyzed in this
retrospective study during January and March, 2010. The
retrospective and cross-sectional analysis study was ap-
proved by the Institutional Review Board of National
Taiwan University Hospital, and this study was carried out
without any linkage of personal information for all partici-
pants. All subjects received abdominal ultrasonography by
gastro-hepatology specialists blinded to all information
concerning these subjects during health investigation. All
patients completed ultrasonographic investigation by a
convex 3.5-MHz transducer (HPM2410A, Hewlett
Packard, Andover, MA, USA). Usually, non-alcoholic fatty
liver disease (NAFLD) diagnostic criteria included charac-
teristic echo patterns of hepatorenal contrast, bright liver,
deep attenuation, and vascular blurring. Fatty pancreas
was diagnosed when there was an increase in echogenicity
of the pancreatic body over that of the kidney. As the
pancreas could not be compared simultaneously with the
kidney in the same sonographic window, the investigatorscompared the difference between hepatic and renal
echogenicity, and between hepatic and pancreatic
echogenicity to obtain an objective pancreato-renal
echo contrast [10]. Subjects were divided into the fatty
pancreas group (n = 72) and the normal pancreas group
(n = 485) according to the ultrasonographic diagnosis.
Physical and biochemical findings
The height, weight, abdominal girth (AG), pulse rate,
systolic blood pressure (SBP), and diastolic blood pressure
(DBP) of all subjects were measured routinely in the
health check-up program. AG was measured in the mid-
section between the lowest rib and the iliac crest of the
pelvis and horizontal to the ground with the subject in an
upright position. BMI and AG/height were determined for
all subjects. Blood samples were tested routinely after
an 8 h fast for complete blood cell count (CBC), liver
function, amylase concentration, fasting blood glucose
(FBG) concentration, HbA1c, total cholesterol, trigly-
ceride (TG) concentration, high density lipoprotein
cholesterol (HDL-C), and low density lipoprotein chol-
esterol (LDL-C). Two h postprandial blood glucose
(PBG) measurements were also performed routinely.
Definition of metabolic syndrome
The criteria for diagnosis of metabolic syndrome were
those of the National Cholesterol Education Program
Adult Treatment Panel III (ATP III). Metabolic syndrome
was diagnosed when three or more of the following were
present: abdominal obesity (waist circumference ≥ 90 cm
for males or ≥ 80 cm for females), increased TG concen-
tration (≥150 mg/dL), decreased HDL-C (< 40 mg/dL
for males or < 50 mg/dL for females), hypertension (sys-
tolic blood pressure, SBP ≥ 130/diastolic blood pressure,
DBP ≥ 85 mm Hg), and impaired FBG concentration
(≥110 mg/dL).
Statistical analyses
Descriptive data are presented as means ± SD for con-
tinuous variables. Differences between the fatty pancreas
and normal pancreas group were determined using the
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tionship between fatty pancreas and metabolic syn-
drome. A p value < 0.05 was considered statistically
significant. All statistical analyses were performed with
SPSS 12.0.
Results
A total of 557 individuals, 315 men and 242 women,
without known hypertension or diabetes were included.
Among them, 72 were diagnosed with fatty pancreas
according to the trans-abdominal ultrasonographic find-
ings; 30 (41.7%) were male and 42 (58.3%) were female.
These subjects constituted the fatty pancreas group. The
remaining 485 subjects, of whom 285 were male and
200 were female, comprised the normal pancreas group.
Table 1 presents the demographic characteristics and
laboratory findings for the two groups. As compared to
the normal pancreas group, the fatty pancreas group was
characterized by a significantly higher mean age, BMI,
and AG in both males and females, by significantly
higher FBG, PBG, HbA1c, total cholesterol, TG, and
LDL-C values, and by a significantly higher platelet
count (all p <0.03). By contrast, no differences in HDL-C
or DBP between the two groups were observed. Interest-
ingly, serum amylase values were lower in the fatty pan-
creas group as compared to the normal pancreas group
(p <0.01).
No statistically significant differences between the
two groups were observed for liver function tests in-
volving aspartate aminotransferase (25.6 ± 10.3 U/L vs.Table 1 Demographic characteristics and laboratory







Gender (M:F) 315:342 30:42 285:200
Age (years)* 50.8±12.4 57.3±12.4 20.7±12.8
FBG (mg/dl) 104.7±29.4 95.1±20.6
AG (cm)* 89.8±8.1 84.3±9.4
SBP (mm HG)# 123.2±18.1 118.3±16.8
DBP (mm Hg) 72.7±11.2 70.1±11.1
TG (mg/dl)* 142.5±81.8 111.5±70.9
HDL-C (mg/dl) 46.8±10.4 48.8±11.5
Amylase(U/L)* 93.2±26.6 102.3±36.2
HbA1c (%)* 5.8±0.9 5.5±0.7
BMI* 25.3±2.7 23.7±3.5
Girth/Height* 0.56±0.05 0.50±0.06
PLT (×10)* 263.7±64.7 242.3±56.9
*p<0.01, #: p=0.023.
FBG, fasting blood glucose concentration; PBG, postprandial blood glucose
concentration; AG, abdominal girth; SBP, systolic blood pressure; DBP, diastolic
blood pressure; TG, triglycerides; HDL-C, high density lipoprotein-cholesterol;
PLT, platelets.25.5 ± 9.3 U/L, p = 0.92), alanine aminotransferase
(31.4 ± 27.9 U/L vs. 29.1 ± 19.4 U/L, p = 0.39), and γ-
glutamyl transpeptidase (22.0 ± 16.7 U/L vs. 24.5 ±
28.0 U/L, p = 0.46) measurements or for tumor
markers including carcinoembryonic antigen (0.9 ±
0.6 ng/mL vs. 1.1 ± 0.7 ng/mL, p = 0.06) and carbohy-
drate antigen 19–9 (12.5 ± 14.9 U/mL vs. 13.0 ± 0.7 U/mL,
p = 0.65).
The prevalence of each parameter of metabolic syn-
drome among subjects in each group is presented in
Table 2. Greater abdominal obesity, increased incidence
of hypertension, higher TG values, decreased HDL-C
values, and higher FBG concentrations were found for
subjects with, as compared to without, fatty pancreas (all
p <0.01).
Each of the two study groups was examined for the
percentages of subjects displaying varying degrees of pa-
rameters for metabolic syndrome (Table 3). The percent-
ages of subjects displaying 1, 2, 3, 4 or 5 parameters and
the mean number of parameters were both higher for
the fatty pancreas group (all p <0.01). Among the 110
subjects diagnosed with metabolic syndrome (presence
of 3 or more parameters), a significantly greater percent-
age were also diagnosed with fatty pancreas (p <0.01).
Discussion
The present study reveals significant associations of fatty
pancreas with aging, obesity, systolic hypertension,
hyperglycemia, and dyslipidemia. As compared to subjects
without fatty pancreas, a significantly greater percentage
of subjects with this condition were also diagnosed with
metabolic syndrome. It should be noted that all subjects
in this study received abdominal ultrasonography by
gastrointestinal specialists blinded to all demographic and
laboratory findings for these subjects.
Controversy has surrounded the association of fatty
pancreas with advanced age. For example, findings fromTable 2 Prevalence of each parameter of metabolic
syndrome in the study group
Metabolic parameters Fatty pancreas n (%) Normal pancreas n (%)
Abdominal obesity* 52 (72.2%) 214 (44.1%)
TG* 28 (38.9%) 93 (19.2%)
HDL* 32 (44.4%) 161 (33.2%)
HTN* 24 (33.3%) 128 (26.4%)
FBG* 34 (47.2%) 95 (19.6%)
*p <0.01.
Abbreviations: TG, triglycerides; HDL, high density lipoproteins; HTN,
hypertension; FBG, fasting blood glucose.
The five criteria of the metabolic syndrome as established by the National
Cholesterol Education Program’s Adult Treatment Panel III are: abdominal
obesity (waist circumference ≥ 90 cm for males or ≥ 80 cm for females),
hypertension (SBP ≥ 130/DBP ≥ 85 mm Hg), triglyceride concentrations
≥150 mg/dL, HDL-cholesterol <40 mg/dL for males or <50 mg/dL for females,
and fasting glucose concentrations ≥110 mg/dL.
Table 3 Number of parameters of metabolic syndrome
for subjects in the two groups
Number of metabolic Fatty pancreas Normal pancreas
Syndrome parameters n (%) n (%)
0 4 (5.6%) 156 (32.2%)
1 22 (30.6%) 132 (27.2%)
2 21 (29.2%) 112 (23.1%)
3 16 (22.2%) 54 (11.1%)
4 7 (9.7%) 27 (5.6%)
5 2 (2.8%) 4 (0.8%)
Meet ≥ 3 criteria* 25 (34.7%) 85 (17.5%)
Mean number* 2.1 ± 1.2 1.3 ± 1.2
*p <0.01.
The five criteria of the metabolic syndrome as established by the National
Cholesterol Education Program’s Adult Treatment Panel III are: abdominal
obesity, hypertension, triglyceride concentrations ≥150 mg/dL, HDL-cholesterol
<40 mg/dL for males or <50 mg/dL for females, and fasting glucose
concentrations ≥110 mg/dL.
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studies are consistent with this association. However, no
such association was observed in another prospective
EUS study [10].
Association between NAFPD and the parameter of
metabolic syndrome
The definition criteria for metabolic syndrome are
thought not ideal, and controversies continue over the
validity of its predictive value for cardiovascular events
and diabetes due to several factors as no inclusion of
age, gender, LDL-C, family history or past history of
cardiovascular disease and diabetes in the definition cri-
teria. However, Tenenbaum et al. showed that current
available evidences strongly supported that metabolic
syndrome is an important clustering of cardiovascular
risk factors and diabetes [19].
In the present study, fatty pancreas was found to be
strongly associated with specific parameters of metabolic
syndrome. For example, an association with obesity as
manifested by increased BMI and AG was observed.
This finding is compatible with those of an autopsy re-
port [18] and with those of several human fatty pancreas
studies involving the use of ultrasonography [13], EUS
[10,11,17], CT [20], and MRI [12,14,15]. In animal study,
Mathur et al. also documented that obese mice have
heavier pancreas and more pancreatic fat, especially
triglycerides, and concluded that obesity leads to fat
infiltration of the pancreas [21]. In the present study,
fatty pancreas was also found to be associated with sys-
tolic, but not diastolic, hypertension; this finding is in
agreement with that of Choi et al. [17]. Additionally,
fatty pancreas was found to be associated with increased
FBG, PBG, and HbA1c values. In this regard it should
be noted that findings of previous studies of theassociation between fatty pancreas and hyperglycemia
are inconsistent. No association between fatty pancreas
and DM and/or FBG was found in two studies [10,13]
whereas in others fatty pancreas was found to correlate
inversely with insulin secretion and β–cell function and
directly with impaired glycemia and DM [12,14,16]. In
the present study, fatty pancreas was also found to be
strongly associated with hyperlipidemia as manifested by
increased total cholesterol, TG, and LDL-C values; how-
ever, no association of HDL-C with fatty pancreas was
observed. These findings differ somewhat from those of
Lee et al. [13] who reported that fatty pancreas is associ-
ated with increased total cholesterol, TG, HDL, and free
fatty acid concentrations but not with increased LDL-C
concentrations. Sepe et al. [10] reported that fatty pan-
creas was associated with hyperlipidemia but lipid pro-
files were not provided in this report. In the present
study, fatty pancreas was found to be strongly associated
with the frequency of metabolic syndrome and to correl-
ate with the number of the parameters of metabolic
syndrome. These findings are consistent with those of
previous studies [10,13].
Although central obesity had been defined as essential
criteria of metabolic syndrome, Lee, et al. reported that
the incidence of diabetes in subjects without central
obesity was similar to that in subjects with central obes-
ity in a Chinese hypertensive family cohort study. This
indicated central obesity is not essential component of
metabolic syndrome for predict diabetes [22]. In present
study, fatty pancreas was found to be associated with in-
creased FBG, PBG, and HbA1c values, and its predictive
value of diabetes need to be further evaluated.
Association between NAFPD and NAFLD
The fatty pancreas and normal pancreas groups did not
differ with respect to liver function. No differences be-
tween the two groups were observed regarding albumin
and globulin concentrations and AST, ALT, and γGT
values. This finding is somewhat surprising in that fatty
liver has been reported to be associated with fatty pan-
creas, and elevation of liver enzymes, especially of ALT,
is often present in subjects with fatty liver. Findings of
EUS studies showed an association of fatty pancreas with
hepatic steatosis [10,11,17], and findings of one MRI
study revealed a correlation of pancreatic fat content
with liver fat content [15]. Furthermore, findings of a
trans-abdominal ultrasonographic study showed a cor-
relation between fatty pancreas and liver enzymes in-
cluding AST, ALT, and γGT [13]. The findings of one
autopsy study demonstrated that total pancreatic fat is
significantly correlated with NAFLD, and fatty liver and
fatty pancreas are related more significant in women
[23]. In contrast, no association between pancreatic fat
and liver fat was found in other MRI studies [12,16].
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cases with fatty pancreas concurrently had fatty liver, but
most subjects (97%) with fatty liver had fatty pancreas.
The positive predictive value of fatty liver in fatty pancreas
was around 70%, but the negative predictive value of fatty
liver in normal pancreas was high to 96%. These findings
suggested that fatty pancreas could be an initial indicator
of ectopic fat deposition and an earlier manifestation of
metabolic syndrome than fatty liver [13].
No statistically differences in markers of pancreatic
carcinoma, including CEA and CA 19–9, were observed
between the fatty pancreas and control groups. These
findings are consistent with those of a previous study
[10] in which fatty pancreas was not found to be associ-
ated with pancreatic carcinoma.
Association between NAPFD and pancreatic enzymes
Two additional findings of the present report are of par-
ticular interest. The first is that serum amylase values
were significantly lower for the fatty pancreas as com-
pared to normal pancreas group. This finding contrasts
with that of Sepe et al. [10] who found no association
between fatty pancreas and serum amylase or lipase
concentrations. It is known that elevated serum amylase
levels often accompany acute pancreatitis and are occa-
sionally caused by other conditions such as pancreatic
tumors. However, few clinical studies investigating clin-
ical implications of low serum amylase. Low serum
amylase was thought due to diffuse pancreas destruction
secondary to advanced pancreatitis [24,25]. Low serum
amylase was also associated with insulin resistance in
obese animal models [26,27]. Nakajima et al. showed
that low serum amylase is associated with increased risk
of metabolic abnormalities, metabolic syndrome, and
diabetes, and provided a pancreatic exocrine-endocrine
relationship in certain clinical condition [28]. Lower






Al-Haddad M, et al. [11] 120 (60/60) EUS BMI, hepatic s
Sepe PS, et al. [10] 230 (64/166) EUS BMI, fatty liver
Choi CW, et al. [17]. 284 (174/110) EUS Hepatic steato
tobacco male
Lee JS, et al. [13] 293 (180/113) Trans-abd
ominal US
IR, VAT, ALT, M
Heni M et al. [12] 51 MRI BMI, VAT, wais
Lingvay I, et al. [14] 79 MRI BMI, hyperglyc
Sijens PE, et al. [15] 36 MRI BMI, liver fat
Tushuizen ME, et al. [16] 36 (12/24) MRI Beta-cell dysfu
IR, insulin resistance; DM, diabetes mellitus; MetS, metabolic syndrome; ALT, alanine
pancreas; NP, normal pancreas; EUS, endoscopic ultrasonography; US, ultrasonograppossibly reflected diffuse destruction of pancreas due to
fat infiltration. The second is that the platelet count was
significantly higher for the fatty pancreas as compared to
normal pancreas group. To our knowledge, the present
study is the first to examine this relationship. Further
exploration of the associations of fatty pancreas with
serum amylase and platelet count is planned.Previous studies focused on NAFPD
Table 4 summarizes prior findings regarding factors asso-
ciated with fatty pancreas. Based on a number of currently
conflicting findings, further studies of the associations of
fatty pancreas with age, hyperglycemia, hyperlipidemia,
fatty liver, and serum amylase are warranted. Some limi-
tations of this study need to be noted. Owing to its
cross-sectional case–control retrospective fashion, we
only demonstrated the relation between fatty pancreas
and metabolic syndrome, and the long-term effect of
presence of fatty pancreas to metabolic syndrome was
uncertain due to lack of longitudinal data. There was no
fasting insulin measurement in the routine health inves-
tigation, and insulin resistance was unable to calculate.Conclusion
In conclusion, non-alcoholic fatty pancreatic disease
(NAFPD or fatty pancreas) may represent a meaningful
manifestation of metabolic syndrome. The associations
of fatty pancreas with age, hyperglycemia, hyperlipidemia,
fatty liver, serum amylase, and platelet count require fur-
ther examination. The incidental abdominal ultrasono-
graphic finding of fatty pancreas in a subject without
known metabolic syndrome but abdominal obesity should
alert further investigation. Further cohort study should be
carried out to observe serial changes of fatty pancreas in
diabetic and non-diabetic subjects.ed with non-alcoholic fatty pancreas
ctors No correlation
teatosis, alcohol





t circumference Fatty liver
emia
nction Fatty liver, VAT
aminotransferase; HTN, hypertension; VAT, visceral adipose tissue; FP, fatty
hy; FBG, fasting blood glucose; LDL-C, low density lipoprotein-cholesterol.
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